Cancer Research CR Helping Patients Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takino, T.
Right arrow Articles by Sato, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takino, T.
Right arrow Articles by Sato, H.
[Cancer Research 63, 2335-2337, May 1, 2003]
© 2003 American Association for Cancer Research

Tumor Biology

CrkI Adapter Protein Modulates Cell Migration and Invasion in Glioblastoma1

Takahisa Takino2, Mitsutoshi Nakada, Hisashi Miyamori, Junkoh Yamashita, Kenneth M. Yamada and Hiroshi Sato

Departments of Molecular Virology and Oncology, Cancer Research Institute [T. T., H. M., H. S.], and Neurosurgery, Division of Neuroscience [M. N., J. Y.], Graduate School of Medical Science, Kanazawa University, Kanazawa 920-0934, Japan, and Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, NIH, Bethesda, Maryland 20892-4370 [K. M. Y.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS AND DISCUSSION
 REFERENCES
 
The human crk gene is translated into crkI and crkII by alternative splicing. crkII mRNA was detected both in normal brain and glioblastoma tissues, whereas crkI mRNA levels were quite low in normal brain and up-regulated in glioblastoma tissues. Expression of CrkI but not CrkII in glioblastoma U87MG cells induced transformation that stimulated cell migration and invasion concomitant with tyrosine phosphorylation of p130 Crk-associated substrate. N-cadherin-mediated signal transduction, which was essential for invasion by U87MG cells, was no longer required for CrkI-transformed cells. These results suggest that CrkI contributes to malignancy of glioblastoma by inducing phosphorylation of p130 Crk-associated substrate.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS AND DISCUSSION
 REFERENCES
 
Crk was originally isolated as an oncogene product of the CT10 chicken retrovirus, and it belongs to a group of adapter proteins that are comprised of SH23 and SH3 domains, which interact with phosphotyrosine and proline-rich regions, respectively (1 , 2) . The SH2 domain of Crk can bind to p130cas, paxillin, and growth factor receptors. The N-terminal SH3 domain of Crk can bind to C3G (guanine nucleotide exchange factor for Rap1), Sos (guanine nucleotide exchange factor for Ras), DOCK180 (which activates Rac1 after binding to the CrkII/p130cas complex), c-Abl, and PI 3-K p85 regulatory subunit (2) . The human crk gene is translated into two products, CrkI (Mr 28,000) and CrkII (Mr 42,000), by alternative splicing (3) . CrkII, which is predominantly expressed in many cell lines, consists of one SH2 and two SH3 domains with a spacer region between the SH3 domains that includes a tyrosine phosphorylation site, Tyr221 (2) . On tyrosine phosphorylation, CrkII undergoes intramolecular binding, which results not only in blockade of CrkII SH2-mediated binding to phosphotyrosine residues in other molecules but also in reduced affinity of the CrkII central SH3 domain (2 , 4, 5, 6) . In contrast, CrkI consists of one SH2 and only one SH3 domain, and it lacks this tyrosine phosphorylation site. Because CrkI but not CrkII expression induces transformation in rat 3Y1 fibroblasts, CrkI appears to resemble the v-crk oncogene product not only in its structure but also in its function (2 , 3) . CrkII has been implicated in FAK-induced cell migration by coupling with p130cas (6 , 7) ; however, the expression and function of CrkI in tumor cells are poorly understood. In the present study, we demonstrated specific expression of crkI in glioblastoma tissues and analyzed the role of CrkI in malignancy of glioblastoma.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS AND DISCUSSION
 REFERENCES
 
RNA Extraction and RT-PCR Analysis.
Fresh human glioblastoma tissues were obtained from five patients, and normal brain tissues were taken from the margin of surgical specimens. The classification of human brain tumors used in this study is based on the revised WHO criteria for tumors of the central nervous system (8) . All of the tumor tissues were obtained at primary resection, and none of the patients had been subjected to chemotherapy or radiation therapy. RT-PCR was carried out using the following PCR primers based on human crkI and crkII cDNA (GenBank accession nos. NM_005206 and NM_016823, respectively): (a) crk 5'-primer starting at nucleotide 336 of CrkII, 5'-GCCTCCGCCCGGGGTGAGCCCCTC, and (b) crk 3'-primer starting at nucleotide 953 of CrkII, 5'-CGTTTGCCATTACACCCCCCTTCC. The PCR products amplified with these primers were 618 bp for CrkII and 448 bp for CrkI, respectively.

Antibodies and Reagents.
Antiphosphotyrosine (PY20), anti-p130cas, anti-Crk, anti-FAK, anti-paxillin, anti-N-cadherin, and anti-ß-catenin antibodies were purchased from Transduction Laboratories. Anti-C3G antibody was from Santa Cruz Biotechnology. N-cadherin blocking mouse monoclonal antibody (GC-4), PI 3-K inhibitor LY294002, and DMEM were from Sigma-Aldrich. Anti-phospho-Akt (Ser473) and anti-Akt antibodies were from New England Biolabs.

Cell Motility Assay.
U87MG (1.5 x 106) cells were electroporated with 10 µg of pcDNA-CrkI or pcDNA-CrkII together with 5 µg of pRK-green fluorescent protein and 5 µg of pHA262pur puromycin-resistance plasmids. The cells were subcultured at a 1:3 dilution 12 h after transfection and maintained a further 48 h in 1.5 µg/ml puromycin-containing medium. After puromycin selection, cells were replated onto 35-mm glass bottom dishes coated with 10 µg/ml fibronectin and cultured in DMEM containing 2 mg/ml BSA. Cell movements were measured using time-lapse video microscopy.

Cell Invasion Assay.
Cell invasion was assayed using modified Boyden chambers consisting of Transwell membrane filters (Corning Costar Corp.) as described (9) . The top surfaces of the Transwell membranes were coated with 1 mg/ml Matrigel basement membrane matrix (Becton Dickinson Labware) overnight at 4°C. Serum-starved cells (2 x 105) suspended in 100 µl of DMEM containing 1 mg/ml BSA and 0.5% serum were cultured in chambers with or without LY294002 (10 µM) or GC-4 (dilution 1:50) for 16 h, and then the number of cells on the bottom surface was counted.


   RESULTS AND DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS AND DISCUSSION
REFERENCES
 
crkI and crkII mRNA Expression in Glioblastoma Tissues.
To investigate the expression of crkI and crkII mRNA in normal brain and glioblastoma tissues, we designed PCR primers to amplify the alternatively spliced regions (nucleotides 713–882 in crkII mRNA) that distinguish crkI from crkII (Fig. 1A)Citation . crkII mRNA was detected both in normal brain and glioblastoma tissues at comparable levels (Fig. 1B)Citation . In contrast, crkI mRNA was quite low in normal brain but up-regulated to the level of crkII mRNA in glioblastoma tissues (P < 0.05). This is, to the best of our knowledge, the first demonstration that crkI but not crkII mRNA expression is specifically up-regulated in glioblastoma tissues.



View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. crkI and crkII mRNA expression in glioblastoma tissues. A, schematic representation of CrkI and CrkII structure. Filled bars, cording region; SH2, SH2 domain; SH3, SH3 domain; P, a tyrosine phosphorylation site (Tyr221). Arrows, PCR primers. In B, total RNA from normal brain (N) and glioblastoma tissue (T) was examined for crkI, crkII, and GAPDH mRNA expression by RT-PCR. C, relative crk expression normalized against GAPDH. Open bar, crkII/GAPDH; filled bar, crkI/GAPDH; *, P < 0.05 versus normal brain.

 
CrkI Promotes Cell Migration.
To compare the function of CrkI and CrkII, U87MG cells were cotransfected with pHA262pur puromycin resistance plasmids and CrkII or CrkI expression plasmids, and transfectants were tested for migration rates on fibronectin after selection with puromycin. Expression of CrkII did not significantly affect migration of U87MG cells, but CrkI expression enhanced migration by 30% compared with mock or CrkII-transfected cells (P < 0.001; Fig. 2ACitation ). In association with increased cell migration, p130cas was more effectively tyrosine phosphorylated in CrkI-transfected cells compared with control or CrkII-transfected cells. Increased p130cas tyrosine phosphorylation is known to activate Rac1 by forming a complex with Crk and DOCK180 (7 , 10 , 11) . These results suggest that CrkI expression promotes cell migration by activating the FAK/p130cas/CrkI/DOCK180 pathway.



View larger version (23K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. CrkI accelerates cell migration. In A, cell motilities of U87MG cells transfected with CrkI, CrkII, or control vector on fibronectin (10 µg/ml) were measured by time-lapse video microscopy for 3 h. Error bars, SD for >=30 cells/condition (*, P < 0.001 versus control). In B, parallel cultures on fibronectin for 12 h were homogenized, immunoprecipitated with anti-p130cas (IP: p130cas) antibody, and immunoblotted with anti-phosphotyrosine (Blot: pTyr) or anti-p130cas (Blot: p130cas) antibodies. The whole-cell lysates (WCL) were immunoblotted with anti-Crk antibody (Blot: Crk).

 
Transformation of U87MG Cells by CrkI.
Fig. 3ACitation shows the morphology of the cells stably transfected with CrkI at 12 or 72 h after incubation in DMEM with or without serum (labeled 10% fetal bovine serum and SFM, respectively). U87MG cells and mock transfectants formed branching colonies with multilayering, especially in serum-free medium, whereas stable CrkI transfectants grew dispersed. Dissociation of branching colonies was also observed in cells transiently transfected with CrkI but not CrkII (data not shown). Although CrkI-expressing cells did not form branching colonies, the expression of N-cadherin and ß-catenin was not significantly altered in these cells (Fig. 3B)Citation . On the other hand, tyrosine phosphorylation of p130cas and C3G was substantially augmented in CrkI-expressing cells, whereas that of FAK and paxillin was not altered (Fig. 3C)Citation . Increased tyrosine phosphorylation of p130cas and C3G is known to activate Rac1 and Rap1, respectively (10, 11, 12) . Rac1 is involved in both the assembly and disassembly of adherens junctions (13) . C3G-dependent Rap1 activation promotes cell adhesion and spreading (14) . Overexpression of CrkII promotes breakdown of adherens junctions and spreading of breast cancer epithelial T47D cells (15) . Therefore, CrkI reconstitution in U87MG cells may induce activation of Rac1 and Rap1 by enhancing tyrosine phosphorylation of p130cas and C3G, resulting in transformation stimulating cell migration and dissociating branching colonies.



View larger version (65K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Stable expression of CrkI in U87MG cells. A, morphology of CrkI-expressing cells. Mock and CrkI-expressing U87MG cells at 80% confluence were further cultured for 12 or 72 h either without serum free media (SFM) or with serum (10% fetal bovine serum). Magnification, x100. B and C, mock and CrkI-expressing U87MG cells were serum starved for 12 h, homogenized, and immunoprecipitated with anti-FAK (IP: FAK), anti-p130cas (IP: p130cas), anti-C3G (IP: C3G), or anti-paxillin (IP: Paxillin) antibodies and then immunoblotted with anti-phosphotyrosine (Blot: pTy), anti-FAK (Blot: FAK), anti-p130cas (Blot: p130cas), anti-C3G (Blot: C3G), or anti-paxillin (Blot: Paxillin) antibodies. The whole-cell lysates were immunoblotted with anti-Crk (Blot: Crk), anti-N-cadherin (Blot: N-Cad), or anti-ß-catenin (Blot: ß-Cat) antibodies.

 
CrkI Promotes Cell Invasion.
Invasive cells must coordinately regulate cell migration and survival. In fact, p130cas/Crk coupling facilitates both cell invasion and survival in a Rac-dependent manner (16) . Because N-cadherin-mediated intercellular interaction promotes cell survival by activating the PI 3-K/Akt pathway (17) , treatment of glioblastoma cells with N-cadherin-blocking antibody GC-4 suppresses invasion (18) . On the other hand, U87MG cells transformed by CrkI grow without cell–cell interaction as described above. Consequently, we examined the effect of N-cadherin-blocking antibody GC-4 on PI 3-K/Akt activation in CrkI-transformed cells (Fig. 4A)Citation . When mock and CrkI-transformed U87MG cells were cultured on Matrigel, Akt was phosphorylated to comparable levels. Although treatment of control U87MG cells with GC-4 antibody preferentially inhibited PI 3-K/Akt activation, CrkI-transformed cells were resistant to it. Invasion by both mock and CrkI-transfected cells was inhibited by the PI 3-K inhibitor LY294002, indicating that the PI 3-K/Akt pathway is essential for invasion. Consistent with its effects on Akt activation, GC-4 suppressed invasion of mock transfected but not CrkI-transformed cells. The PI 3-K/Akt pathway is constitutively activated in v-Crk-transformed chicken embryo fibroblasts (19) . Similarly, in CrkI-transformed U87MG cells, the PI 3-K/Akt pathway is constitutively activated; moreover, N-cadherin-mediated cell–cell interaction is lost and no longer essential for invasion and survival. The expression of CrkI in U87MG cells enhanced invasiveness by 70% compared with that of control cells, which may be explained in part by enhanced migration through the activation of the FAK/p130cas/Crk/DOCK180 pathway by CrkI as described above.



View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. CrkI promotes cell invasion via PI 3-K activation. In A, mock and CrkI-transfected U87MG cells were serum starved overnight, trypsinized, suspended at 4 x 105 cells in 0.2 ml of 2 mg/ml BSA/DMEM, and replated onto Matrigel-coated dishes in the presence or absence of GC-4 (dilution 1:50) for 16 h and then homogenized and immunoblotted with anti-phospho-Akt (Blot: pAkt), anti-Akt (Blot: Akt), or anti-Crk (Blot: Crk) antibodies. In B, cell invasion assays were carried out as described in "Materials and Methods." Bars, SE from three independent experiments; *, P < 0.001; **, P < 0.005 versus control.

 
The U87MG cell line is defective in the tumor suppressor gene PTEN (phosphatase and tensin homologue deleted from chromosome 10) and expresses N-cadherin (9 , 18) . Inhibition of U87MG cell invasion by phosphatase and tensin homologue deleted from chromosome 10 expression or treatment with GC-4 antibody is accompanied by suppression of the PI 3-K/Akt pathway (Fig. 4ACitation ; Refs. 9 and 20 ). Thus, CrkI seems to be a key molecule in signaling networks that coordinately regulate cell–cell adhesion, cell spreading, migration, and survival.

We have demonstrated here that expression of crkI but not crkII is specifically up-regulated in glioblastoma tissues, which contributes to malignancy of glioblastoma while activating p130cas. CrkI is also involved in promoting the invasive phenotype by activating PI 3-K/Akt signaling without N-cadherin-mediated intercellular interactions. CrkI may not only be a diagnostic marker but also a molecular target for drug development against glioblastoma.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by a Grant-in-Aid for Science Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology, Japan (Grant 14028025 to T. T. and Grant B2-11240203 to H. S.). Back

2 To whom requests for reprints should be addressed, at Department of Molecular Virology and Oncology, Cancer Research Institute, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-0934, Japan. Phone: 81-76-265-2750; Fax: 81-76-234-4505; E-mail: ttakino{at}kenroku.kanazawa-u.ac.jp Back

3 The abbreviations used are: SH, Src homology; FAK, focal adhesion kinase; PI 3-K, phosphatidylinositol 3-kinase; p130cas, p130 Crk-associated substrate; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RT-PCR, reverse transcription-PCR. Back

Received 12/10/02. Accepted 3/ 5/03.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS AND DISCUSSION
 REFERENCES
 

  1. Mayer B. J., Hamaguchi M., Hanafusa H. A novel viral oncogene with structural similarity to phospholipase C. Nature (Lond.), 332: 272-275, 1988.[Medline]
  2. Feller S. M., Posern G., Voss J., Kardinal C., Sakkab D., Zheng J., Knudsen B. S. Physiological signals and oncogenesis mediated through Crk family adapter proteins. J. Cell. Physiol., 177: 535-552, 1998.[Medline]
  3. Matsuda M., Tanaka S., Nagata S., Kojima A., Kurata T., Shibuya M. Two species of human CRK cDNA encode proteins with distinct biological activities. Mol. Cell. Biol., 12: 3482-3489, 1992.[Abstract/Free Full Text]
  4. Rosen M. K., Yamazaki T., Gish G. D., Kay C. M., Pawson T., Kay L. E. Direct demonstration of an intramolecular SH2-phosphotyrosine interaction in the Crk protein. Nature (Lond.), 374: 477-479, 1995.[Medline]
  5. Okada S., Matsuda M., Anafi M., Pawson T., Pessin J. E. Insulin regulates the dynamic balance between Ras and Rap1 signaling by coordinating the assembly states of the Grb2-SOS and CrkII-C3G complexes. EMBO J., 17: 2554-2565, 1998.[Medline]
  6. Kain K. H., Klemke R. L. Inhibition of cell migration by Abl family tyrosine kinases through uncoupling of Crk-CAS complexes. J. Biol. Chem., 276: 16185-16192, 2001.[Abstract/Free Full Text]
  7. Klemke R. L., Leng J., Molander R., Brooks P. C., Vuori K., Cheresh D. A. CAS/Crk coupling serves as a "molecular switch" for induction of cell migration. J. Cell Biol., 140: 961-972, 1998.[Abstract/Free Full Text]
  8. Kleihues P. Burger P. C. Scheithauer B. W. eds. . Histological Typing of Tumours of the Central Nervous System, 11-20, Springer-Verlag Berlin 1993.
  9. Tamura M., Gu J., Takino T., Yamada K. M. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res., 59: 442-449, 1999.[Abstract/Free Full Text]
  10. Kiyokawa E., Hashimoto Y., Kobayashi S., Sugimura H., Kurata T., Matsuda M. Activation of Rac1 by a Crk SH3-binding protein, DOCK180. Genes Dev., 12: 3331-3336, 1998.[Abstract/Free Full Text]
  11. Kiyokawa E., Hashimoto Y., Kurata T., Sugimura H., Matsuda M. Evidence that DOCK180 up-regulates signals from the CrkII-p130(Cas) complex. J. Biol. Chem., 273: 24479-24484, 1998.[Abstract/Free Full Text]
  12. Ichiba T., Hashimoto Y., Nakaya M., Kuraishi Y., Tanaka S., Kurata T., Mochizuki N., Matsuda M. Activation of C3G guanine nucleotide exchange factor for Rap1 by phosphorylation of tyrosine 504. J. Biol. Chem., 274: 14376-14381, 1999.[Abstract/Free Full Text]
  13. Braga V. Epithelial cell shape: cadherins and small GTPases. Exp. Cell Res., 261: 83-90, 2000.[Medline]
  14. Ohba Y., Ikuta K., Ogura A., Matsuda J., Mochizuki N., Nagashima K., Kurokawa K., Mayer B. J., Maki K., Miyazaki J., Matsuda M. Requirement for C3G-dependent Rap1 activation for cell adhesion and embryogenesis. EMBO J., 20: 3333-3341, 2001.[Medline]
  15. Lamorte L., Royal I., Naujokas M., Park M. Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions. Mol. Biol. Cell, 13: 1449-1461, 2002.[Abstract/Free Full Text]
  16. Cho S. Y., Klemke R. L. Extracellular-regulated kinase activation and CAS/Crk coupling regulate cell migration and suppress apoptosis during invasion of the extracellular matrix. J. Cell Biol., 149: 223-236, 2000.[Abstract/Free Full Text]
  17. Li G., Satyamoorthy K., Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res., 61: 3819-3825, 2001.[Abstract/Free Full Text]
  18. Kotelevets L., van Hengel J., Bruyneel E., Mareel M., van Roy F., Chastre E. The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness. J. Cell Biol., 155: 1129-1135, 2001.[Abstract/Free Full Text]
  19. Akagi T., Murata K., Shishido T., Hanafusa H. v-Crk activates the phosphoinositide 3-kinase/AKT pathway by utilizing focal adhesion kinase and H-ras. Mol. Cell. Biol., 22: 7015-7023, 2002.[Abstract/Free Full Text]
  20. Tamura M., Gu J., Danen E. H., Takino T., Miyamoto S., Yamada K. M. PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J. Biol. Chem., 274: 20693-20703, 1999.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
T. Takino, H. Saeki, H. Miyamori, T. Kudo, and H. Sato
Inhibition of Membrane-Type 1 Matrix Metalloproteinase at Cell-Matrix Adhesions
Cancer Res., December 15, 2007; 67(24): 11621 - 11629.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Nakada, K. L. Drake, S. Nakada, J. A. Niska, and M. E. Berens
Ephrin-B3 Ligand Promotes Glioma Invasion through Activation of Rac1.
Cancer Res., September 1, 2006; 66(17): 8492 - 8500.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
T. Watanabe, M. Tsuda, Y. Makino, S. Ichihara, H. Sawa, A. Minami, N. Mochizuki, K. Nagashima, and S. Tanaka
Adaptor Molecule Crk Is Required for Sustained Phosphorylation of Grb2-Associated Binder 1 and Hepatocyte Growth Factor-Induced Cell Motility of Human Synovial Sarcoma Cell Lines
Mol. Cancer Res., July 1, 2006; 4(7): 499 - 510.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Takino, M. Nakada, H. Miyamori, Y. Watanabe, T. Sato, D. Gantulga, K. Yoshioka, K. M. Yamada, and H. Sato
JSAP1/JIP3 Cooperates with Focal Adhesion Kinase to Regulate c-Jun N-terminal Kinase and Cell Migration
J. Biol. Chem., November 11, 2005; 280(45): 37772 - 37781.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
S. P. Rodrigues, K. E. Fathers, G. Chan, D. Zuo, F. Halwani, S. Meterissian, and M. Park
CrkI and CrkII Function as Key Signaling Integrators for Migration and Invasion of Cancer Cells
Mol. Cancer Res., April 1, 2005; 3(4): 183 - 194.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Iwahara, T. Akagi, Y. Fujitsuka, and H. Hanafusa
CrkII regulates focal adhesion kinase activation by making a complex with Crk-associated substrate, p130Cas
PNAS, December 21, 2004; 101(51): 17693 - 17698.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Tsuda, Y. Makino, T. Iwahara, H. Nishihara, H. Sawa, K. Nagashima, H. Hanafusa, and S. Tanaka
Crk Associates with ERM Proteins and Promotes Cell Motility toward Hyaluronic Acid
J. Biol. Chem., November 5, 2004; 279(45): 46843 - 46850.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. P. Venables
Aberrant and Alternative Splicing in Cancer
Cancer Res., November 1, 2004; 64(21): 7647 - 7654.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Nakada, J. A. Niska, H. Miyamori, W. S. McDonough, J. Wu, H. Sato, and M. E. Berens
The Phosphorylation of EphB2 Receptor Regulates Migration and Invasion of Human Glioma Cells
Cancer Res., May 1, 2004; 64(9): 3179 - 3185.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
R. Blindt, A.-K. Bosserhoff, J. Dammers, N. Krott, L. Demircan, R. Hoffmann, P. Hanrath, C. Weber, and F. Vogt
Downregulation of N-cadherin in the neointima stimulates migration of smooth muscle cells by RhoA deactivation
Cardiovasc Res, April 1, 2004; 62(1): 212 - 222.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Takino, H. Miyamori, Y. Watanabe, K. Yoshioka, M. Seiki, and H. Sato
Membrane Type 1 Matrix Metalloproteinase Regulates Collagen-Dependent Mitogen-Activated Protein/Extracellular Signal-Related Kinase Activation and Cell Migration
Cancer Res., February 1, 2004; 64(3): 1044 - 1049.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
T. Takino, M. Tamura, H. Miyamori, M. Araki, K. Matsumoto, H. Sato, and K. M. Yamada
Tyrosine phosphorylation of the CrkII adaptor protein modulates cell migration
J. Cell Sci., August 1, 2003; 116(15): 3145 - 3155.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takino, T.
Right arrow Articles by Sato, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takino, T.
Right arrow Articles by Sato, H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online